Pierre Meulien

Title: Pierre Meulien: Innovator in Biotechnological Advancements

Introduction

Pierre Meulien is a notable inventor based in Strasbourg, France. He has made significant contributions to the field of biotechnology, particularly in the development of cell lines and DNA sequences related to human factor IX. With a total of 3 patents, his work has paved the way for advancements in medical research and therapeutic applications.

Latest Patents

One of Pierre Meulien's latest patents involves the creation of cell lines from transgenic mice that express biologically active human factor IX. These cell lines are engineered with a first exogenous DNA sequence that encodes human factor IX, regulated by a hepatic cell-specific promoter. Additionally, a second exogenous DNA sequence encoding an oncogene is included, which is also controlled by a hepatic cell-specific promoter. This innovative approach allows for the production of biologically active human factor IX, which can be isolated from the culture media. Another significant patent relates to a novel DNA sequence coding for factor IX or a similar protein, where specific codons are strategically placed to enhance expression.

Career Highlights

Throughout his career, Pierre Meulien has worked with various organizations, including Transgene S.A. and his own company, Pierre Meulien. His expertise in genetic engineering and biotechnology has led to groundbreaking discoveries that have implications for therapeutic treatments.

Collaborations

Pierre has collaborated with notable colleagues such as Andrea Pavirani and Frederic Perraud. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Pierre Meulien's innovative work in biotechnology, particularly in the area of human factor IX, showcases his dedication to advancing medical science. His patents reflect a commitment to improving therapeutic options and enhancing our understanding of genetic engineering.